{"id":64281,"date":"2026-04-30T13:46:47","date_gmt":"2026-04-30T05:46:47","guid":{"rendered":"https:\/\/flcube.com\/?p=64281"},"modified":"2026-04-30T13:46:48","modified_gmt":"2026-04-30T05:46:48","slug":"hutchmeds-sovleplenib-granted-nmpa-priority-review-for-warm-antibody-autoimmune-hemolytic-anemia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64281","title":{"rendered":"HutchMed&#8217;s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia"},"content":{"rendered":"\n<p><strong>HutchMed (China) Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/HCM:NASDAQ\">NASDAQ: HCM<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/0013:HKG\">HKG: 0013<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has accepted its market approval filing for <strong>sovleplenib<\/strong>, granting <strong>priority review status<\/strong> for the treatment of adult patients with <strong>warm antibody autoimmune hemolytic anemia (wAIHA)<\/strong> who have had an inadequate response to at least one prior course of glucocorticoid therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Review Status<\/strong><\/td><td>Priority review<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Sovleplenib (oral)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Treatment of adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) refractory to glucocorticoid therapy<\/td><\/tr><tr><td><strong>Filing Date<\/strong><\/td><td>April 2026<\/td><\/tr><tr><td><strong>Additional Designation<\/strong><\/td><td>Breakthrough Therapy Designation (BTD) granted in March 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Novel, selective, oral small-molecule inhibitor<\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>Spleen tyrosine kinase (Syk)<\/strong> \u2013 a key signaling protein in immune cell activation and B-cell receptor signaling<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First-in-class Syk inhibitor specifically developed for wAIHA in China, with potential applications across hematological malignancies and autoimmune diseases<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Late-stage clinical development with breakthrough designation reflecting substantial improvement over available therapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-amp-regulatory-context\">Clinical &amp; Regulatory Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Patient Population<\/strong><\/td><td>Adults with wAIHA who failed at least one course of glucocorticoid therapy<\/td><\/tr><tr><td><strong>Unmet Need<\/strong><\/td><td>Limited treatment options for glucocorticoid-refractory wAIHA; current second-line therapies include rituximab, splenectomy, or immunosuppressants with significant side effects<\/td><\/tr><tr><td><strong>Regulatory Pathway<\/strong><\/td><td>Priority review typically reduces standard review timeline from 200 to 130 working days<\/td><\/tr><tr><td><strong>Market Opportunity<\/strong><\/td><td>wAIHA affects approximately 17 per 100,000 people in China, with ~30% of patients becoming refractory to first-line glucocorticoid therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Autoimmune Disease Landscape:<\/strong> Growing recognition of rare autoimmune disorders with increasing regulatory support for innovative therapies addressing unmet needs<\/li>\n\n\n\n<li><strong>Competitive Position:<\/strong> Sovleplenib would be the first targeted Syk inhibitor approved specifically for wAIHA in China, differentiating from broad immunosuppressants<\/li>\n\n\n\n<li><strong>Commercial Strategy:<\/strong> HutchMed likely to leverage existing hematology commercial infrastructure and partnerships with specialized treatment centers<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Positive NMPA outcome could support regulatory filings in other markets, particularly given the novel mechanism of action<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory timelines and commercial expectations for sovleplenib. Actual results may differ due to risks including final approval decisions, clinical outcomes, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that China&#8217;s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1105,285,38,1104,24],"class_list":["post-64281","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-hkg-0013","tag-hutchmed","tag-market-approval-filings","tag-nasdaq-hcm","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HutchMed&#039;s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that China&#039;s National Medical Products Administration (NMPA) has accepted its market approval filing for sovleplenib, granting priority review status for the treatment of adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) who have had an inadequate response to at least one prior course of glucocorticoid therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64281\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HutchMed&#039;s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia\" \/>\n<meta property=\"og:description\" content=\"HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that China&#039;s National Medical Products Administration (NMPA) has accepted its market approval filing for sovleplenib, granting priority review status for the treatment of adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) who have had an inadequate response to at least one prior course of glucocorticoid therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64281\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T05:46:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-30T05:46:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64281#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64281\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HutchMed&#8217;s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia\",\"datePublished\":\"2026-04-30T05:46:47+00:00\",\"dateModified\":\"2026-04-30T05:46:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64281\"},\"wordCount\":358,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 0013\",\"HutchMed\",\"Market approval filings\",\"NASDAQ: HCM\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64281#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64281\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64281\",\"name\":\"HutchMed's Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-30T05:46:47+00:00\",\"dateModified\":\"2026-04-30T05:46:48+00:00\",\"description\":\"HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that China's National Medical Products Administration (NMPA) has accepted its market approval filing for sovleplenib, granting priority review status for the treatment of adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) who have had an inadequate response to at least one prior course of glucocorticoid therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64281#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64281\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64281#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HutchMed&#8217;s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HutchMed's Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia - Insight, China&#039;s Pharmaceutical Industry","description":"HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that China's National Medical Products Administration (NMPA) has accepted its market approval filing for sovleplenib, granting priority review status for the treatment of adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) who have had an inadequate response to at least one prior course of glucocorticoid therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64281","og_locale":"en_US","og_type":"article","og_title":"HutchMed's Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia","og_description":"HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that China's National Medical Products Administration (NMPA) has accepted its market approval filing for sovleplenib, granting priority review status for the treatment of adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) who have had an inadequate response to at least one prior course of glucocorticoid therapy.","og_url":"https:\/\/flcube.com\/?p=64281","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-30T05:46:47+00:00","article_modified_time":"2026-04-30T05:46:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64281#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64281"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HutchMed&#8217;s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia","datePublished":"2026-04-30T05:46:47+00:00","dateModified":"2026-04-30T05:46:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64281"},"wordCount":358,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 0013","HutchMed","Market approval filings","NASDAQ: HCM","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64281#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64281","url":"https:\/\/flcube.com\/?p=64281","name":"HutchMed's Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-30T05:46:47+00:00","dateModified":"2026-04-30T05:46:48+00:00","description":"HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that China's National Medical Products Administration (NMPA) has accepted its market approval filing for sovleplenib, granting priority review status for the treatment of adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) who have had an inadequate response to at least one prior course of glucocorticoid therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64281#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64281"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64281#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HutchMed&#8217;s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64281","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64281"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64281\/revisions"}],"predecessor-version":[{"id":64282,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64281\/revisions\/64282"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64281"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64281"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}